

Please type a plus sign (+) inside this box ☐

Approved for use through 09/30/2000. OM 8 0551-0000
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/05 (4/95)

S. PTO
87-433887

01/28/00

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))

Attorney Docket No. **BEIERSDORF 602-WCG**

First Inventor or Application Identifier **Dr. Norbert ETTNER**

Title **"PROTEIN-CONTAINING HYDROGELS"**

Express Mail Label No. **EE473057695US**

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

- ☒ * Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
- ☒ Specification [Total Pages **31**]
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
- ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets **2**]
- Oath or Declaration [Total Pages **1**]
 - ☒ Newly executed (original or copy)
 - ☐ Copy from a prior application (37 C.F.R. § 1.63(d))
(for continuation/divisional with Box 16 completed)
 - ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).

NOTE FOR ITEMS 1 & 13: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28)

ADDRESS TO:

Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

- ☐ Microfiche Computer Program (Appendix)
- Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - ☐ Computer Readable Copy
 - ☐ Paper Copy (identical to computer copy)
 - ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

- ☒ Assignment Papers (cover sheet & document(s))
- ☐ 37 C.F.R. §3.73(b) Statement (when there is an assignee) ☒ Power of Attorney
- ☐ English Translation Document (if applicable)
- ☒ Information Disclosure Statement (IDS/PTO-1449) ☒ Copies of IDS Citations
- ☒ Preliminary Amendment
- ☒ Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
- ☐ Small Entity Statement (PTO/SB/06-12) ☐ Statement filed in prior application, Status still proper and desired
- ☒ Certified Copy of Priority Document(s) (if foreign priority is claimed)
- Other: _____

16. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: _____

Prior application information: Examiner _____ Group / Art Unit: _____

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

17. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label (Insert Customer No. or Attach bar code label here) or ☒ Correspondence address below

Name	William C. Gerstenzang			
	NORRIS, McLAUGHLIN & MARCUS, P.A.			
Address	660 White Plains Road			
City	Tarrytown	State	New York	Zip Code 10591
Country	U.S.A.	Telephone	914-332-1700	Fax 914-332-1844

Name (Print/Type)	William C. Gerstenzang	Registration No. (Attorney/Agent)	27,552
Signature	<i>William C. Gerstenzang</i>	Date	Jan. 28, 2000

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231

Attorney Docket No. : Beiersdorf 602-WCG
: 6713-St-ka

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Dr. Norbert ETTNER, Dr. Michael SCHINK, Dr. Jörg SCHREIBER, Dr.
Wolfgang MEIER, Marc SAUER

Serial No. : To Be Assigned

Filed : Herewith

For : PROTEIN-CONTAINING HYDROGELS

Art Unit : To Be Assigned

Examiner : To Be Assigned

January 28, 2000

BOX PATENT APPLICATION
Hon. Assistant Commissioner
for Patents
Washington, D. C. 20231

PRELIMINARY AMENDMENT

Sir:

Prior to examination, please amend the above-identified application as follows:

IN THE CLAIMS:

Claim 1 (amended). Hydrogel comprising at least one protein, [and/or] enzyme [and] or SOD/catalase enzyme mimic, or a combination thereof, and PEGs, and parts of proteins and enzymes, [and/or] recombinant proteins and enzymes, or a combination thereof the proteins [and/or], enzymes or both being connected to the PEGs via urea groups.

Claim 2 (amended). Hydrogel according to Claim 1, [characterized in that] wherein the PEG has a molecular weight of from [8.000 to 18.000] 8.000 to 18.000 g/mol, in particular from 10,000 to 15,000 g/mol.

Claim 3 (amended). Hydrogel according to [Claims 1 and 2, characterized in that] Claim 1, wherein aliphatic or aromatic or araliphatic diisocyanates, [in particular 1,6-hexamethylene diisocyanate,] are employed to activate the PEGs.

Claim 4 (amended). Hydrogel according to [Claims 1 to 3, characterized in that] Claim 1, wherein antibodies, matrix metalloproteases, enzyme inhibitors, or peptides are used as proteins.

Claim 5 (amended). Hydrogel according to [Claims 1 to 4, characterized in that] Claim 1, wherein free radical scavengers [such as] selected from the group consisting of superoxide dismutase, catalase, glutathione peroxidase, myeloperoxidase [and], SOD/catalase enzyme mimics and[/or] combinations thereof are used as proteins.

Claim 6 (amended). Hydrogel according to [Claims 1 to 5, characterized in that] Claim 1, wherein enzymes with antimicrobial activity[, such as lysozyme and hydrolases,] are employed as proteins.

Claim 7 (amended). Hydrogel according to [Claims 1 to 6, characterized in that] Claim 1, wherein enzymes with phosphorylating activity[, such as phosphatases and

kinases,] are employed as proteins.

Claim 8 (amended). Hydrogel according to [Claims 1 to 7, characterized in that] Claim 1, wherein growth factors [such as PDGF] are employed as proteins.

Claim 9 (amended). Hydrogel according to [Claims 1 to 8, characterized in that] Claim 1, wherein enzymes with proteolytic activity[, such as collagenase, trypsin, elastase and/or combinations thereof,] are employed as proteins.

Claim 10 (amended). Hydrogel according to [Claims 1 to 9, characterized in that] Claim 1, wherein proteinogenic protease inhibitors [such as aprotinin, soya bean trypsin inhibitor and alpha-2-macroglobulin and/or combinations thereof] are employed as proteins.

Claim 11 (amended). Hydrogel according to [Claims 1 to 10, characterized in that] Claim 1, wherein proteins are employed in mixtures.

Claim 12 (amended). Process for producing a hydrogel according to [at least one of the preceding claims, characterized in that] Claim 1, wherein

- e) anhydrous PEGs are reacted with diisocyanate in a solvent, [where appropriate] optionally with the addition of a catalyst,
- f) the solvent is removed from the resulting product of activated PEGs by filtration, washing or drying.

- g) the activated PEGs are reacted in aqueous solution with proteins, the proteins being present in a buffer which is [preferably] optionally chosen so that the proteins retain their biological activity.
- h) [where appropriate] optionally, purification steps and washes are carried out.

Claim 13 (amended). Process for producing a hydrogel according to Claim 12, wherein [characterized in that] the hydrogel is dehydrated.

Claim 14 (amended). [Use of the hydrogel according to at least one of the preceding claims as] A wound dressing[, in particular] for deep and extensive chronic wounds, and burns which comprises the hydrogel according to Claim 1.

Claim 15 (amended). [Use of the hydrogel according to at least one of the preceding claims for application to substrate materials which are permeable to air and water vapour, where appropriate, such as] B[b]andages, compresses, plasters, sheets[, and] films [and the like] comprising the hydrogel of Claim 1.

Please add the following claims:

--16. The hydrogel of Claim 3, wherein said diisocyanate is 1,6-hexamethylene diisocyanate.

17. The hydrogel of Claim 6, wherein said enzyme is selected from the group consisting of lysozyme and hydrolases.

18. The hydrogel of Claim 1, wherein said enzyme is selected from the group consisting of phosphatases and kinases.

19. The hydrogel of Claim 8, wherein said growth factor is PDGF.

20. The hydrogel of Claim 9, wherein said enzymes are selected from the group consisting of collagenase, trypsin, elastase and combinations thereof.--

REMARKS

This preliminary amendment is being filed to eliminate multiple dependency, and to conform the claims to conventional format

Favorable action is respectfully solicited.


ADDITIONAL FEE

Please charge any insufficiency of fees, or credit any excess, to Deposit Account

No. 14-1263.

Respectfully submitted,

NORRIS, McLAUGHLIN & MARCUS, P.A.

By 

William C. Gerstenzang

Reg. No. 27,552

WCG:kts

660 White Plains Road
Tarrytown, New York 10591-5144
(914) 332-1700

**Beiersdorf Aktiengesellschaft
Hamburg**

Description

Protein-containing hydrogels

The healing of therapy-resistant wounds has since time immemorial been a great challenge to medicine and science. Present-day specifications for the function of interactive dressings for chronic wounds derive from Winter (1962, Nature 193, 293) and have recently been reformulated by Turner (1994, Wound Rep. Reg. 2, 202). The emphasis in this connection is on the creation of a moist wound healing environment which, in contrast to traditional dry wound treatment with, for example, gauze compresses, provides physiological and thus better conditions for the natural processes of wound healing.

The principle of moist wound healing can at present be regarded as the state of the art in the therapy of wounds which are healing with difficulty or not at all. The dressing must absorb most of the exudate but, at the same time, leave on the wound itself a liquid film in which the actual moist wound healing takes place. Dry wounds and those with little exudation must be provided with adequate moisture to achieve rehydration of the dehydrated tissue. In the moist wounds which have been established in this way there is then proliferation of new blood vessels and reduced bacterial growth, with a suitable pH being set up. These requirements are met by sponge-like structures such as, for example, hydrogels which have an excess in the form of bound water.

Hydrogels are generally produced by hydrophilic, coherent monomers forming in a dispersant a three-dimensional network structure into whose interstices the dispersant, normally water, can infiltrate. A hydrogel should have a certain oxygen permeability and assume a barrier function towards microbes possibly penetrating in from the environment. Fundamental requirements for a hydrogel are also a simple production process and a certain storage stability.

The use and the variety of possible uses of hydrogels in wound treatment, and their composition and production are sufficiently well documented (Peppas in: *Hydrogels in Medicine and Pharmacy*, 1986, CRC Press, Volume II, Chapter 4). Hydrogels are preferably employed for treating dry necrotic wounds such as, for example, burns and chronic venous ulcers (Thomas, in: *Wound Management and Dressings*, 1990, The Pharmaceutical Press, London, p. 50).

They are made of insoluble polymeric materials able to swell in aqueous media. They should furthermore have a high water content, be inert to biological processes, permeable for cellular metabolites and, in particular, not induce any irritation on contact with living tissue.

A bioartificial or semisynthetic hydrogel can be synthesized by covalently linking the hydrophilic synthetic monomer to the surface of a protein, whereupon there is formation of a three-dimensional polymer-protein matrix inside the dispersant. This class of hydrogels made from synthetic polymers and biopolymers have recently become the subject of research. These novel biomaterials are referred to as bioartificial hydrogels (Giusti et al., 1993, *Trends in Polymeric Science*, 9, 261).

US 5,804,213 reports on the production of a biologically active, water-containing gel as wound dressing. In this case, a dry, hydrocolloidal polymer is mixed with water and a biologically active substance.

The use of dehydrated, crosslinked collagen materials as drug delivery system is described in WO 98/22153. In WO 96/31551, proteins or peptides in the dry state are mixed as active agents with polyurethane-crosslinked microgels. The microgels swell in an aqueous medium to give hydrogels and release the protein or peptide again from the hydrogel matrix. Moreover US 5,000,955 describes polyurethane hydrogels for cosmetic, biological and medical applications.

Cubic phases made of glyceryl monooleate are able to immobilize enzymes by non-covalent linkages, as reported in WO 96/39125. In this case, the enzymatic activity is retained due to the immobilization and is even increased over a lengthy period by comparison with dissolved enzyme. It should furthermore be emphasized that the barrier function of the gel matrix suppresses the proteolytic degradation of the immobilized enzymes occurring in the wound fluid.

Hydrogels of particular interest are those in which a biomolecule is covalently incorporated, as described in US 5,733,563 and in 1994 by Fortier (1994,

Biotechnol. Techn., 8, 71). These hydrogels are formed by copolymerization of a polyethylene glycol which has been activated by 4-nitrophenyl chloroformate and of bovine serum albumin in borate buffer. In this case, the activated group may react with an amino, SH-, OH- or COOH group in the protein.

Disadvantages of the bioartificial hydrogels known in the state of the art are the long gel times of from 20 up to 270 minutes, the formation of cleavage products in the form of p-nitrophenols in the hydrogel matrix and the impossibility of crosslinking oligomeric proteins such as, for example dimeric SOD or tetrameric catalase stably with the polyethylene glycol which has been activated with 4-nitrophenyl chloroformate.

It is an object of the invention to make water-insoluble, water-swellaable hydrogels which have short gel times, can be employed for medical purposes and are particularly suitable for promoting the healing of chronic wounds.


This object is achieved by a hydrogel which comprises at least one protein and/or enzyme and PEGs, the proteins and/or enzymes being connected to the PEGs via urea groups.

In the production of the hydrogel there is use of additional substances which interact with the oxygen species (ROS) present in wound fluids of chronic wounds, that is to say with factors which impede the wound healing process, these additional substances being covalently polymerized into the hydrogel. The invention describes the novel production of protein-containing hydrogels with which it is possible to render ROS in the wound fluid of chronic wounds harmless. It describes the production of collagenase-containing and trypsin-containing hydrogels for treating necrotic deposits covering wounds, and the production of lysozyme-containing hydrogels which can be employed for controlling bacteria which have infected wounds. The feasibility of incorporating biologically active substances such as, for example, antibiotics, growth factors and other active ingredients into the hydrogels is also described.

The present invention makes use of the reaction of, in particular, α,ω -diisocyanato-polyethylene glycols with protein to form a protein-containing hydrogel in an aqueous medium. In this case, the crosslinking reaction of the isocyanate with the amino groups of the protein is a reaction which is preferred owing to the higher nucleophilicity by comparison with hydrolysis of the isocyanate to the amine with formation of carbon dioxide. The reaction represents one possibility for the three-dimensional crosslinking of polyethylene glycol and proteins without the occurrence of cleavage products

resulting from the activated group. It is furthermore possible to form stable hydrogels with oligomeric proteins such as, for example, SOD and catalase.

Polyethylene glycols (PEGs) belong to the class of polyalkylene glycols which are polyethers of the general formula (Römpf Lexikon Chemie – Version 1.3, Stuttgart/New York: Georg Thieme Verlag 1997):



Polyethylene glycols (PEGs) are produced industrially by base-catalysed polyaddition of ethylene oxide (oxirane) in systems which usually contain small amounts of water with ethylene glycol as starter molecule. They have molecular weights in the range of about 200–5 000 000 g/mol, corresponding to degrees of polymerization n of about 5 to >100 000. In the wider sense, products with $n=2-4$ (di-, tri- and tetraethylene glycol) are also included in the PEGs; they can be produced mol. uniformly, whereas the PEGs with higher molecular weights are polymol, that is to say consist of populations of macromolecules with different molecular weights.

Liquid products with molecular weights < about 25 000 g/mol are referred to as proper polyethylene glycols, while the solid ones of higher molecular weight (melting point about 65°C) are referred to as polyethylene oxides. Polyethylene oxides have an extremely low concentration of reactive hydroxyl end groups and show only weak glycol properties.

Branched polyadducts of ethylene glycol and polyhydric alcohols are also referred to as PEG.


PEG are liquid or waxy to solid products which are readily soluble in water up to about 100°C and many organic solvents. Aqueous solutions have noticeable rheological properties; thus, some solutions show pronounced viscoelasticity. Even tiny amounts of PEG cause the so-called Toms effect (a reduction in frictional resistance) in flowing water. PEG products are very stable to hydrolysis but sensitive to oxidation at elevated temperatures. Their chemical reactivity is determined by the terminal hydroxyl groups, which are easily esterified (to give polyethylene glycol esters) or etherified (to give polyalkylene glycol ethers) or can be reacted with isocyanates to give urethanes.

PEG are categorized as toxicologically acceptable. Their biodegradability is very dependent on the molecular weight; products with low molecular weights, for example 4000 g/mol, are up to 80% degraded.

PEGs are used inter alia as solubilizers, binders, thickeners, emulsifiers, dispersants, protective colloids, plasticizers or release agents for a wide variety of applications; as binders for ceramic compositions, sizes, flocculants, adhesive components, to reduce the resistance to flow of aqueous liquids (drag reduction), as intermediates for polymer syntheses, for example on a large scale for producing polyurethanes; high molecular weight PEGs as starch substitute and for producing films and sheets.


The PEG employed advantageously has a molecular weight of from 8,000 to 18,000 g/mol, in particular 10,000 to 15,000 g/mol.


It is also possible according to the invention to employ modified PEGs, which may have the following structural schemes:




where B symbolizes a hydrophilic region in the particular crosslinker molecule, and A represents an isocyanate group, and which may differ in chemical nature within one molecule.

Likewise within the scope of the invention submitted herewith are structural schemes as follows:





(12)







(13)

where Z in this case represents a central unit which may be hydrophilic or hydrophobic and usually comprises an oligo- or polyfunctional molecular residue.

Linker substances with a higher degree of branching of course also fall within the scope of the present invention.


For example, Z in the scheme (10) may comprise a glyceryl radical whose three OH functionalities pass over into the B regions which in turn may represent, for example, polyoxyethylene chains of equal or unequal length, and whose terminal OH group is esterified with a long chain fatty acid. Partial substitution on the glycerol is also conceivable and may result in structures corresponding to scheme (9).

Possible examples of more specific structural schemes for structural scheme (1) are as follows:




where R_1 , R_2 , R_3 , R_4 , R_5 and R_6 represent, independently of one another, isocyanate groups or branched or unbranched, saturated or unsaturated, cyclic or chain-like aliphatic, aromatic or heteroaromatic radicals, for example branched or unbranched or cyclic alkyl or alkanoyl radicals, or aryl or aroyl radicals which are unsubstituted or substituted by alkyl or aryl substituents, or else alkylated or arylated organylsilyl radicals, but where at least one of these radicals represents an isocyanate group. In this connection, x , y and z denote, independently of one another, numbers which allow the complete molecule to be soluble or at least dispersible in water, typically selected from the range above 10, advantageously from the range from 20 to 10^7 . a and b are numbers which are selected depending on x so that the linker substance has an at least adequate stability in water or dispersibility in water. It is possible in individual cases, for example when the thickener is chosen from the group of derivatized polysaccharides, for x to assume where appropriate considerably higher values than, for example, 300, even several millions. This is known per se to the skilled person and requires no further explanation.

Possible examples of more specific structural schemes for structural scheme (2) are as follows:




where R_1 , R_2 and R_3 may represent, independently of one another, isocyanate groups or branched or unbranched, unsaturated or saturated, cyclic or chain-like aliphatic, aromatic or heteroaromatic radicals, for example branched or unbranched or cyclic alkyl or alkanoyl radicals, or aryl or aroyl radicals which are unsubstituted or substituted by alkyl or aryl substituents, or else alkylated or arylated organylsilyl radicals, but where at least one of these radicals represents an isocyanate group. In this case, x , y and z denote, independently of one another, numbers which permit the complete molecule to be soluble or at least dispersible in water, typically chosen from the range above 10, advantageously from the range from 20 to 10^7 .

Possible examples of more specific structural schemes for the structural scheme (3) are as follows:




It is also, of course, true in this case that partial substitution is conceivable, in which case one or more of the indices u, v, w, x may assume the value zero, and one or more of the radicals R_1, R_2, R_3 or R_4 may represent hydrogen atoms. In this case, these substances naturally pass over into other structural schemes.


Possible examples of more specific structural schemes for structural scheme (9) are as follows:



where R_1 , R_2 , R_3 and R_4 may represent, independently of one another, isocyanate groups or branched or unbranched, unsaturated or saturated, cyclic or chain-like aliphatic, aromatic or heteroaromatic radicals, for example branched or unbranched or cyclic alkyl or alkanoyl radicals, or aryl or aroyl radicals which are unsubstituted or substituted by alkyl or aryl substituents, or else alkylate or arylated organylsilyl radicals, but where at least one of these radicals represents an isocyanate group. In this case, x , y and z denote, independently of one another, numbers which permit the complete molecule to be soluble or at least dispersible in water, typically chosen from the range above 10, advantageously from the range from 20 to 10^7 .

Possible examples of more specific structural schemes for the structural scheme (10) are as follows:




[illegible]

where R₁, R₂, R₃ and R₄ may represent, independently of one another, isocyanate groups or branched or unbranched, saturated or unsaturated, cyclic or chain-like aliphatic, aromatic or heteroaromatic radicals, for example branched or unbranched or cyclic alkyl or alkanoyl radicals, or aryl or aroyl radicals which are unsubstituted or substituted by alkyl or aryl substituents, or else alkylated or arylated organylsilyl radicals, but where at least one of these radicals represents an isocyanate group. In this case, x, y and z denote, independently of one another, numbers which permit the


complete molecule to be soluble or at least dispersible in water, typically chosen from the range above 10, advantageously from the range from 20 to 10^7 .

A possible example of a more specific structural scheme for structural scheme (12) is as follows:



where R_1 , R_2 , R_3 , R_4 and R_5 may represent, independently of one another, isocyanate groups or branched or unbranched, saturated or unsaturated, cyclic or chain-like aliphatic, aromatic or heteroaromatic radicals, for example branched or unbranched or cyclic alkyl or alkanoyl radicals, or aryl or aroyl radicals which are unsubstituted or substituted by alkyl or aryl substituents, or else alkylated or arylated organylsilyl radicals, but where at least one of these radicals represents an isocyanate group. In this case, x , y and z denote, independently of one another, numbers which permit the complete molecule to be soluble or at least dispersible in water, typically chosen from the range above 10, advantageously from the range from 20 to 10^7 .

A possible example of a more specific structural scheme for structural scheme (13) is as follows:



where R_1 , R_2 , R_3 , R_4 , R_5 and R_6 may represent, independently of one another, isocyanate groups or branched or unbranched, saturated or unsaturated, cyclic or chain-like aliphatic, aromatic or heteroaromatic radicals, for example branched or unbranched or cyclic alkyl or alkanoyl radicals, or aryl or aroyl radicals which are unsubstituted or substituted by alkyl or aryl substituents, or else alkylated or arylated organylsilyl radicals, but where at least one of these radicals represents an isocyanate group. In this case, x , y and z denote, independently of one another, numbers which permit the complete molecule to be soluble or at least dispersible in water, typically chosen from the range above 10, advantageously from the range from 20 to 10^7 .

It is also advantageous where appropriate for the structural schemes described above to be modified so that renewed branching occurs at the end of the thickener molecule, for example in the way implemented in the group of so-called dendrimers.



The choice of the protein necessary to produce the hydrogel depends on the required properties of the hydrogel. Suitable in principle are all proteins and enzymes, and parts of proteins and enzymes or recombinant proteins and enzymes such as, for example:

- antibodies
- free-radical detoxifying enzymes such as, for example, superoxide dismutase, catalase, glutathione peroxidase, myeloperoxidase and/or combinations thereof, and SOD/catalase enzyme mimics

- enzymes with proteolytic activity, such as collagenase, trypsin, elastase and/or combinations thereof
- protease inhibitors from the class of tissue inhibitors of matrix metalloproteinases (TIMPs) and/or other proteinogenic protease inhibitors such as aprotinin, soya bean trypsin inhibitor and alpha-2 macroglobulin
- enzymes with antimicrobial activity, such as, for example, lysozyme and hydrolase
- enzymes with phosphorylating activity, such as phosphatases and kinases
- growth factors such as, for example, PDGF
- any mixtures of the proteins, in which case the composition of the mixture is likewise oriented to the required functional properties of the hydrogel.

Chosen enzyme inhibitors are, in particular, natural proteinogenic protease inhibitors from the class of TIMPs, and aprotinin, alpha-2-antiplasmin, alpha-2-macroglobulin, alpha-1-antichymotrypsin, soya bean trypsin inhibitor and alpha-1 protease inhibitor.

In the case of a protein-containing hydrogel which comprises SOD, catalase or a mixture of the two enzymes, it is possible to remove ROS selectively from the wound fluid. ROS are secreted in the inflammatory phase of wound healing by neutrophils and monocytes after a cellular stimulus. The enzyme SOD catalyses the dismutation reaction of reactive superoxide to the less toxic intermediates hydrogen peroxide and oxygen (equation 1). It plays the major role in cellular defence against the oxygen-mediated toxicity of ROS and in the regulation of the intracellular oxygen concentration (Fridovich, 1995, Annu. Rev. Biochem., 64, 97). The hydrogen peroxide formed by the SOD reaction is then converted by the redox enzyme catalase, which is ubiquitous in aerobic organisms, in a multistage catalytic cycle into the non-toxic molecules water and oxygen (equation 2) (Gouet et al., 1996, Nature Structural Biology, 3, 951). Apart from catalase, the enzymes glutathione peroxidase and myeloperoxidase are able to break down hydrogen peroxide.



Collagenase-containing ointments have been employed for some years to remove necrotic deposits covering wounds (Nano et al., 1996, in: Proteolysis in Wound

Repair, Abatangelo, Donati and Vanscheidt (Eds.), Springer Verlag, Berlin, page 61) and J. Hansbrough & W. Hansbrough 1996, in: Proteolysis in Wound Repair, Abatangelo, Donati und Vanscheidt (Eds.), Springer Verlag, Berlin, page 97. This involves the enzyme collagenase and other proteases cleaving collagen molecules in the dead tissue and thus making it possible for fibroblasts to migrate in and thus heal the wound (Glyantsev et al., 1997, J. Wound Care, 6, 13). A hydrogel comprising collagenase contributes in a comparable manner to disintegrating the necrotic tissue.

The active enzymes are likewise removed when the hydrogel is removed and do not remain in the wound or in the wound fluid. This interaction includes according to the invention a conversion of the ROS as interfering factors into substances which no longer impede wound healing. The enzymes which are used for the interaction and are covalently bound into the hydrogel are thus only briefly introduced into the wound and are removed from the wound region again after they have performed their intended task (that is to say the abovementioned interactions have started). The selective removal or elimination of the toxic ROS, the proteolytic disintegration of dead tissue and the killing of microorganisms improves or initiates the healing process for chronic, that is to say wounds which are healing with difficulty or not at all.

The protease activity in a chronic wound is found to be distinctly increased (Weckroth et al., 1996, J. Invest. Dermatol., 106, 1119; Grinell & Zhu, 1996, J. Invest. Dermatol. 106, 335) compared with an acute wound. This contrasts with a distinct reduction in the amount of protease inhibitors (Grinell & Zhu, 1996, J. Invest. Dermatol. 106, 335). This imbalance results in proteolytic degradation of proliferation-promoting substances such as, for example, growth factors (Wlaschek et al., 1997, Brit. J. Dermatol., 137, 646). Enzymes such as, for example, SOD and catalase, which act to promote wound healing by their protective action, would thus undergo proteolytic degradation and become inactive. A protein-containing hydrogel into which such enzymes are covalently incorporated acts as a protective shield and is able to prevent attack by proteases, as has been shown with dissolved enzymes modified with polyethylene glycol (Beckman et al., 1988, J. Biol. Chem., 14, 6884; Inada et al., 1995, Tibtech, 13, 86).

It is thus possible within the scope of the present invention not only to generate a moist wound environment in order to improve the healing process for chronic wounds, but also to speed up further according to the invention the healing process by, for example, the abovementioned conversion processes.

Processes for producing the hydrogel according to the invention are explained in detail hereinafter.

In summary, an advantageous process for producing hydrogels according to the invention appears as follows:

- a) anhydrous PEGs are reacted with diisocyanate in a solvent, where appropriate with the addition of a catalyst,
- b) the solvent is removed from the resulting product of activated PEGs by filtration, washing or drying,
- c) the activated PEGs are reacted in aqueous solution with proteins, the proteins being present in a buffer which is preferably chosen so that the proteins retain their biological activity,
- d) where appropriate, purification steps and washes are carried out.

The hydrogel is preferably then dehydrated.

The hydrogel according to the invention is suitable particularly advantageously as wound dressing, in particular for deep and extensive chronic wounds, and burns.

The hydrogel furthermore shows advantageous properties on application to substrate materials which are, where appropriate, permeable to air and water vapour, such as bandages, compresses, plasters, sheets, films and the like.

The individual steps in the process are described in more detail below.

Production of activated α,ω -diisocyanato-polyethylene glycols

The experiments on the production of an activated polyethylene glycol are carried out as described below.

Polyethylene glycols of various molecular weights (6,000 – 35,000 g/mol) are converted by covalent linkage of aliphatic diisocyanates, to form urethane linkages, into α,ω -diisocyanato-polyethylene glycols. In order to avoid hydrolysis of the isocyanate groups employed, the PEG is dehydrated before the actual use. For this purpose, 1.0 mmol of PEG is dissolved in 60 ml of benzene and frozen in liquid nitrogen. The benzene/water azeotrope formed in this way is removed under high vacuum for 7 h.

1.0 mmol of the PEG dehydrated in this way is dissolved in 50 ml of *abs.* dichloromethane while maintaining an argon atmosphere. To this solution are added, for example, 10 mmol of hexamethylene diisocyanate and 1 ml of *abs.* pyridine and stirred at RT for 12 h. The reaction solution was worked up by reprecipitation twice in 800 ml of *abs.* petroleum ether 35/60. The crystalline product was filtered off on a Büchner funnel and washed with *abs.* petroleum ether 35/60 (2 x 100 ml). After drying under high vacuum for 8 h, the activated PEG is stored at -20°C under an argon atmosphere.

It is possible to employ for activating the PEG according to the invention besides 1,6-hexamethylene diisocyanate also other aliphatic or aromatic diisocyanates, for example 1,12-dodecane diisocyanate, isophorone diisocyanate, methylcyclohexane 2,4- and/or 2,6-diisocyanate, dicyclohexylmethane 2,4'- and/or 4,4'-diisocyanate, also cyclobutane 1,3-diisocyanate, cyclohexane 1,3- and 1,4-diisocyanate, 2,4- and/or 2,6-hexahydrotolylene diisocyanate, hexahydro-1,3- and/or 1,4-phenylene diisocyanate, and 1,3- and 1,4-phenylene diisocyanate, 2,4- and 2,6-tolylene diisocyanate, diphenylmethane 2,4'- and/or 4,4'-diisocyanate and naphthylene 1,5-diisocyanate.

Production of protein-containing hydrogels

It has been found, surprisingly, that the novel reaction of the α,ω -diisocyanato-polyethylene glycols with proteins to form protein-containing hydrogels is associated with considerably shorter gel times by comparison with 4-nitrophenyl chloroformate activation.

Fig. 1 is a graphical depiction of the dependence of the gel time on the molecular weight of the α,ω -diisocyanato-polyethylene glycols employed and the pH of the reaction solution. In this, the molecular weight of the PEG employed in gram/mole is depicted on the x axis, and the gel time in seconds is depicted on the y axis. Furthermore, three 0.1 M borate buffer solutions of different pH values are depicted (\circ = pH 9.5, \square = pH 9.0, Δ = pH 8.5).

Figure 2 is a graphical depiction of the dependence of the maximal amount of water which can be absorbed on the ionic strength of the incubation solution. The water content as a percentage of the total weight of the hydrogels is depicted on the x axis,

while the ionic strength of the incubation solution is shown in the form of the borate concentration, increasing from 0–0.2 mol per litre, on the y axis. The depicted experiment took place with hydrogels of the composition 100 mg of PEG₁₅₀₀₀ and 35 mg of BSA.

As described above, it was not previously possible to immobilize proteins, other than albuminoid ones, isolated, in three-dimensional form within a hydrogel matrix. If there was observable gel formation with other proteins or enzymes, they dissolved within a few minutes (see US 5,733,563) and it was possible to achieve only an immobilization as a ternary system consisting of PEG/BSA/enzyme (Fortier et al. 1996. *Enz. Microbiol. Technol.* **18**, 482).

It has further emerged, surprisingly, that the described form of PEG activation via diisocyanates permits immobilization of proteins and enzymes other than albuminoid ones, such as bovine and yeast superoxide dismutase (SOD). For this purpose, 44 mg of superoxide dismutase are dissolved in 2 ml of 0.1 M borate buffer and mixed with 150 mg PEG of various molecular weights. After crosslinking the SOD hydrogels are washed in analogy to BSA hydrogels by incubation in physiological borate buffer, and the washing solution is investigated for uncrosslinked PEG and enzyme. It is found thereby that, under certain conditions, gel formation takes place to result in a stable SOD hydrogel. An essential factor in this connection proves to be the molecular weight and thus the chain length of the polyethylene glycols employed. Gel formation is possible only with difficulty above a molecular weight of PEG₂₀₀₀₀.

In order to estimate the retention of enzymatic activity, samples of the prepared SOD hydrogels are investigated for their activity with the aid of NBT detection (Auclair and Voisin, 1985, in: *CRC Handbook of Methods for Oxygen Radical Research*, CRC Press Inc., Boca Raton). Since this test is suitable only for the quantitative determination of dissolved SOD, it is possible therewith to obtain only qualitative information about the presence of immobilized SOD activity. However, the results obtained suggest that the immobilization within the gel matrix appears to have no significant effect on the activity of the enzyme. Even after storage at various temperatures (4°C, 25°C, 37°C) for several weeks, followed by dehydration under high vacuum and reswelling in incubation solution the enzymic activity present can be observed to be unchanged.

Based on these results, the experiments were extended to other enzymes. This entails testing the crosslinking possibility for the following enzymes:

- bovine catalase
- chicken egg white lysozyme and
- collagenase from *Achromobacter iophagus*.

It is possible with all the said enzymes to obtain a stable hydrogel, the limiting factor being the chain length of the PEG molecule employed.

Table 1:

Crosslinking possibilities for various proteins and enzymes with α,ω -diisocyanato-PEG.

All the experiments took place in 2 ml of 0.1M borate buffer (pH 9.0) with 150 to 300 mg of PEG and 35 to 100 mg of protein/enzyme.

	PEG ₁₅₀₀₀	PEG ₁₀₀₀₀	PEG ₆₀₀₀
BSA	x	x	x
SOD	x	x	x
catalase	x	x	x
collagenase	x	x	
lysozyme	x	x	x
phosphatase		x	x
trypsin		x	x
SOD/catalase	x	x	x

Method for washing the protein-containing hydrogels

After the crosslinking is complete, the hydrogels are incubated in 15 ml of physiological borate buffer (0.1 M H₃BO₃, 0.1 M MgCl₂, 0.1 M CaCl₂, 0.15 M NaCl; pH 7.0) at RT. The incubation solution is changed every 12 hours, and the resulting supernatant is investigated for washed-out protein and PEG. The resulting amounts of protein were evaluated by means of BCA and micro-BCA detection (Brown, Jarvis and Hyland, 1989, Anal. Biochem., 180, 136) and the eluted amounts of PEG were determined with the aid of iodine detection (Sims and Snape. 1980, Anal. Biochem., 107, 60).

The washing is complete when neither protein nor PEG is detectable in the washing solution (incubation between 48 - 72 h). The hydrogels are then stored at RT either in

dehydrated (see the method for dehydrating protein-containing hydrogels) or in swollen form.

Method for dehydrating the protein-containing hydrogels

After completion of the washing process, the gels are dehydrated under high vacuum to constant weight and incubated anew in buffer solutions in order for us to investigate the dependence of the water absorption on various factors such as pH and ionic strength of the hydrogels. The swelling of the gels is followed until the maximum water absorption capacity is reached, by regularly determining the weight, changing the incubation solution every 12 h. The swelling factor (SF) [equation 3] and the maximum water content (EWC) [equation 4] are described by two mathematical relations used for determining the swelling characteristics of polyvinyl alcohol hydrogels (Urushisaki et al., 1990, *Int. J. Pharm.*, 58, 135):

$$\text{Swelling factor (SF)} = (W_s - W_d)/W_d \quad (3)$$

In this, W_s corresponds to the maximum swelling weight achievable and W_d corresponds to the dry weight of the hydrogels. This dry weight is determined after completion of the investigations by drying the gels at 70°C over a period of 24 h. The water content as a percentage of the total weight of the hydrogels can be determined from the data obtained:

$$\text{EWC} = (\text{weight of water/weight of swollen hydrogel}) \times 100 \quad (4)$$

Experiments concerning the swelling characteristics at different pH values and ionic strengths of the incubation solutions have shown that there is a direct connection between these parameters and the swelling capacity of the hydrogels. If, for example, an increase in the ionic strength of the incubation solution causes a decrease in the water absorption capacity, the contrary effect can be observed on changing the pH of the incubation solution. In this case, an increase in the pH leads to an increase in the water absorption capacity.

The effect of the molecular weight of the polyethylene glycols employed on the swelling characteristics of the resulting hydrogels is shown in detail in Table 1.

Table 2:

Evaluation of the swelling parameters (swelling factor SF and water content EWC) of various hydrogels of the following composition: 100 mg of α,ω -diisocyanato-PEG_x and 35 mg of BSA in 2 ml 0.1 M borate buffer solution (pH 9.0).

The following swelling parameters were determined after incubation in physiological borate buffer (0.1 M H₃BO₃, 1 M MgCl₂, 1 M CaCl₂, 0.15 M NaCl; pH 7.0) at RT for 72 h and drying at 70°C for 24 h.

m PEG [g/mol]	SF X	EWC [%]
6,000	29.3	96.7
10,000	35.9	97.3
15,000	43.4	97.7
20,000	47.2	97.9
35,000	63.4	98.5

It should be noted in this connection that the water absorption capacity increases continuously in the direction of higher PEG molecular weights employed. A repetition of the experiment after drying the hydrogels (dehydration under high vacuum to a constant weight) shows irreversibility in relation to the maximum water absorption capacity. In fact, the water contents after renewed swelling following a drying step are 60 - 70% of the water contents achievable before drying.

Concerning the oxygen permeability of the present hydrogels, it can be assumed that, from a water content > 94 % onwards, the oxygen diffusion within the hydrogels will correspond to that of an aqueous solution (Corkhill et al. 1990, Crit. Rev. Biocompatibility., 5, 363).

Method for SOD activity determination

The Biotech SOD-525 assay (OXIS International S.A., France) was employed for measuring the activity of the various SOD enzymes. This assay is based on the increase caused by SOD in the rate constant for the autoxidation reaction of the catechol 5,6,6a,11b-tetrahydro-3,9,10-trihydroxybenzo[c]fluorene (BXT-01050) in

aqueous alkaline solution (Nebot et al., 1993, *Analytical Biochemistry*, **214**, 442). This autoxidation reaction produces a chromophore with a maximum absorption at 525 nm. The assay is carried out in an air-saturated buffer containing 50 mM 2-amino-2-methyl-1,3-propanediol, 0.1 mM diethylenetriaminepentaacetic acid and 3 mM boric acid, pH 8.8, at 37°C. Kinetics are measured at 525 nm within one minute after addition of BXT-01050. The SOD activity is determined by the ratio of the rate constant for the autoxidation reaction V_0/V_c , measured in the presence (V_s) and in the absence (V_c) of the sample. One SOD unit (U-525) is defined as the activity which doubles the background of the autoxidation reaction, that is to say $V_s/V_c = 2$.

Method for catalase activity determination

Catalase (EC 1.11.1.6, Boehringer Mannheim) catalyses the cleavage of hydrogen peroxide (H_2O_2) into oxygen and water. Determination of the activity of the dissolved enzyme takes place using a modification of the spectrophotometric assay of R. F. Beers and I. W. Sizors (J. Biol. Chem. 195, 133 (1952)). The decrease in extinction at 240 nm correlates in this case with the decrease in hydrogen peroxide due to catalase activity in the reaction mixture.

3 ml of phosphate buffer (50 mM, pH 7.0) (reference position) or 3 ml of a phosphate buffer (0.05 mM, pH 7) mixed with H_2O_2 (sample), each with 0.05 ml of the catalase-containing sample, are placed in a quartz cuvette. The hydrogen peroxide concentration in the H_2O_2 -containing buffer is checked by measuring the extinction at 240 nm, the absorption thereof being 0.500 ± 0.01 . After mixing the components in the quartz cuvettes (path length 10 mm), the reaction is observed until the extinction reaches a value of 0.450. The time then taken for the extinction to diminish to 0.400 is then measured using a stop clock. The enzyme concentration in the cuvette is adjusted so that the time needed for this is $20 \text{ s} \pm 2 \text{ s}$. The volume-based activity is calculated by the following formula:

$$\text{volume-based activity [U/ml]} = (17 \times 13) / \text{measured times [s]} \times 0.05$$

$$\text{total activity in the sample [U]} = \text{vol. act. [U/ml]} \times \text{dilution} \times \text{sample volume [ml]}$$

One unit is defined as the enzymic activity which disproportionates $1 \mu\text{mol}$ of hydrogen peroxide per minute under the chosen assay conditions (25°C , pH 7.0).

Method for collagenase activity determination

Collagenase (EC 3.4.24.3, Boehringer Mannheim) catalyses the hydrolytic cleavage of

N-(3[2-furyl]acryloyl)-Leu-Gly-Pro-Ala (FALGPA) (Sigma Chemical Steinheim) at the peptide linkage between the amino acids leucine and glycine in the substrate. The determination of the activity of the dissolved enzyme takes place with a modification of the spectrophotometric assay of H.E. van Wart and D.R. Steinbrink (Anal. Biochem. 113, 356 (1981)). The increase in extinction at 345 nm in this case correlates with the release of coloured N-(3-[2-furyl]acryloyl)-Leu from the substrate due to collagenase activity in the reaction mixture.

In a quartz cuvette (path length 10 mm, Hellma Jena) 2.9 ml of buffer solution (50 mM tricine, 10 mM calcium chloride, 400 mM sodium chloride, pH 7.5) are mixed with 0.1 ml of the collagenase-containing (2 units/ml) sample (sample position) or with 0.1 ml of distilled water (reference position). After mixing the components in the quartz cuvettes and adjusting the temperature to 25°C, the resulting extinction difference at 345 nm is checked over a period of five minutes. The volume-based activity of the sample is calculated by the following formula:

volume-based activity of the sample [U/ml] =

DE nm/min sample - DE nm/min reference position / (0.53) x (mg enzyme/ml reaction mix)

DE = extinction difference

Total activity in the sample [U] = vol.act. [U/ml] x dilution x sample volume [ml]

One unit is defined as the enzymic activity which hydrolyses 1.0 mmol of FALGPA per minute under the chosen assay conditions (25°C, pH 7.5).

Method for trypsin activity determination

Trypsin (EC 3.4.21.4, Sigma Chemical Steinheim) catalyses the cleavage of peptide linkages at the C-terminal end of the amino acids arginine and lysine. The determination of the activity of the dissolved enzyme takes place with a modification of the spectrophotometric assay of Hummel (Can. J. Biochem. Physiol. 37, 1393 (1959)). The increase in extinction at 257 nm correlates with the release of *p*-toluenesulphonyl-L-arginine from *p*-toluenesulphonyl-L-arginine methyl ester (Sigma Chemical Steinheim).

2.6 ml of buffer solution (0.65 M tris(hydroxymethyl)aminomethane, 11 mM calcium chloride dihydrate, pH 8.1) and 0.3 ml of substrate solution (10 mM

p-toluenesulphonyl-L-arginine methyl ester) are placed in a quartz cuvette (path length 10 mm, Hellma Jena), and 0.1 ml of enzyme solution (0.5 U in 1 ml of 0.001 N hydrochloric acid) is added. After mixing in the quartz cuvette and adjusting the temperature to 25°C, the increase in extinction is determined with distilled water as reference over a period of 5 minutes, a constant value per minute being found. The volume-based activity of the sample is calculated by the following formula:

volume-based activity of the sample [U/ml] =

DE nm/min sample x sample volume / (0.54) x (mg enzyme/ml reaction mix)

DE = extinction difference

Total activity of the sample [U] = vol.act. [U/ml] x dilution x sample volume [ml]

One unit is defined as the enzymic activity which brings about the formation of 1 mmol of *p*-toluenesulphonyl-L-arginine per minute under the chosen assay conditions (25°C, pH 7.5).

Method for elastase activity determination

Elastase (EC 3.4.21.36, Sigma Chemical Steinheim) catalyses the cleavage of, for example, elastin to amino acids and peptides. Determination of the activity of the dissolved enzyme takes place with a modification of the spectrophotometric assay of Sacher et al. (Proc. Soc. Exp. Biol. Med. 90, 1955 (1955)). The increase in extinction at 590 nm correlates with the hydrolytic release of orcein from elastin-orcein (Sigma Chemical Steinheim).

20 mg of elastin-orcein are weighed into an Erlenmeyer flask, and 1.5 ml of tris(hydroxymethyl)-aminomethane hydrochloride (197 mM, pH 8.8) are added and equilibrated at 37°C. After addition of 0.5 ml of enzyme solution, the flask is stoppered and stored at 37°C. After addition of 2 ml of phosphate buffer solution (500 mM, pH 6.0) the reaction is stopped after 20 minutes. The mixture is filtered and the flask is rinsed with 1 ml of distilled water. The extinction of 3 ml of sample solution in a quartz cuvette (path length 10 mm, Hellma Jena) is determined at 590 nm, with the reference position comprising 3 ml (2.0 ml of tris(hydroxymethyl)aminomethane hydrochloride (197 mM, pH 8.8), 2.0 ml of phosphate buffer solution (500 mM, pH 6.0) and 1.0 ml of distilled water). The volume-based activity of the sample is calculated by the following formula:

volume-based activity of the sample [U/ml] =

$$E_{590} \times 19.45 - 0.1185 = \text{mg of elastin-orcein cleaved}/(\text{mg enzyme}/0.5 \text{ ml reaction mix})$$

total activity of the sample [U] = vol.act. [U/ml] x dilution x sample volume [ml]

One unit is defined as the enzymic activity which cleaves 1 mg of elastin within 20 min under the chosen assay conditions (37°C, pH 8.8).


Further examples which follow are intended to show particularly advantageous embodiments of the invention without intending unnecessarily to restrict the invention thereby.

Example 1 – Production of hydrogels with serum albumin

The hydrogels are synthesized by covalent crosslinking of α, ω -activated PEG with bovine serum albumin. Various amounts (1 - 20 % m/V) of activated PEG are added to a 2% strength (m/V) protein solution in 0.1 M borate buffer (pH 6.5 - 9.0) and stirred until the onset of the gel point. The hydrogel which is formed is then stored at RT for 12 h to achieve complete crosslinking. Uncrosslinked PEG and protein are removed by incubating the hydrogel in 15 ml of physiological borate buffer (0.1 M H_3BO_3 , 1M MgCl_2 , 1 M CaCl_2 , 0.15 M NaCl ; pH 7.0) for 48 h, changing the washing solutions several times. The amounts of protein eluted thereby are evaluated with the aid of the BCA and micro-BCA detection (Brown, Jarvis and Hyland, 1989, Anal. Biochem., 180, 136) and the eluted amounts of PEG are evaluated by means of the iodine detection (Sims and Snape, 1980, Anal. Biochem., 107, 60).

The crosslinking reaction takes place analogously in 0.05 M sodium bicarbonate buffer with pH values 8.5, 9.0 and 9.3 and in a 0.1 M sodium veronal buffer at pH 9.0. The hydrogels produced in sodium phosphate buffer can be kept stable by changing to physiological borate buffer.

The following depiction shows the crosslinking of PEG₃₅₀₀₀ with bovine serum albumin (BSA) diagrammatically.



Example 2 –Production of hydrogels with superoxide dismutase

The ubiquitous enzyme SOD occurs in dimeric or tetrameric form. The various enzymes with molecular weights from 32,000 to 56,000 Da have metal ions such as copper and zinc (Cu-Zn-SOD), manganese (Mn-SOD) or iron (Fe-SOD) as cofactors in the catalytic centre.

The hydrogels are synthesized by covalent crosslinking of α,ω -activated PEG with bovine and yeast superoxide dismutase. Various amounts (6 - 25% m/V) of activated PEG are added to a 2% strength (m/V) protein solution in 0.1 M borate buffer (pH 9.0) and stirred until the onset of the gel point. Greenish transparent gels are obtained. The hydrogels are then stored at RT for 12 h in order to achieve complete crosslinking. Uncrosslinked PEG and protein are removed by incubating the hydrogels

in 15 ml of physiological borate buffer (0.1 M H_3BO_3 , 0.1 M MgCl_2 , 0.1 M CaCl_2 , 0.15 M NaCl ; pH 7.0) for 48 h changing the washing solutions several times.

Gel formation was observed for the PEG: PEG₂₀₀₀₀, PEG₁₅₀₀₀, PEG₁₀₀₀₀ and PEG₆₀₀₀.

Example 3 – Production of hydrogels with catalase

The most widespread form of catalase is a homotetramer (235.000 Da, bovine liver) with a porphyrin group with one iron atom per subunit.

The hydrogels are synthesized by covalent crosslinking of α,ω -activated PEG with catalase from bovine liver. 7.5% (m/V) activated PEG₁₀₀₀₀ or 15% (m/V) activated PEG₆₀₀₀ are added to a 2.5% strength (m/V) protein solution in 0.1 M borate buffer (pH 9.0) and stirred until the onset of the gel point. Brownish transparent gels are obtained.

The hydrogels are then stored at RT for 12 h in order to achieve complete crosslinking. Uncrosslinked PEG and protein are removed by incubating the hydrogels in 15 ml of physiological borate buffer (0.1 M H_3BO_3 , 0.1 M MgCl_2 , 0.1 M CaCl_2 , 0.15 M NaCl ; pH 7.0) for 48 h changing the washing solutions several times.

Example 4 – Production of hydrogels with superoxide dismutase and catalase

The hydrogels are synthesized by covalent crosslinking of α,ω -activated PEG with yeast superoxide dismutase and bovine liver catalase. 0.8 – 0.15% (m/V) catalase and 5% (m/V) activated PEG are added to a 2.4% (m/V) superoxide dismutase solution in 0.1 M borate buffer (pH 9.0) and stirred until the onset of the gel point. Greenish/brownish transparent gels are obtained.

The hydrogels are then stored at RT for 12 h to achieve complete crosslinking. Uncrosslinked PEG and protein are removed by incubating the hydrogels in 15 ml of physiological borate buffer (0.1 M H_3BO_3 , 0.1 M MgCl_2 , 0.1 M CaCl_2 , 0.15 M NaCl ; pH 7.0) for 48 h, changing the washing solutions several times. Gel formation was observed for PEG₁₀₀₀₀ and PEG₆₀₀₀.

Example 5 – Production of hydrogels with collagenase

The hydrogels are synthesized by covalent linking of α,ω -activated PEG with collagenase from *Achromobacter iophagus*. 7.5 – 15% (m/V) activated PEG₁₅₀₀₀ or activated PEG₁₀₀₀₀ are added to a 5% strength (m/V) protein solution in 0.1 M borate buffer (pH 9.0) and stirred until the onset of the gel point. Reddish/brownish transparent gels are obtained.

The hydrogels are then stored at RT for 12 h to achieve complete crosslinking. Uncrosslinked PEG and protein are removed by incubating the hydrogels in 15 ml of physiological borate buffer (0.1 M H₃BO₃, 0.1 M MgCl₂, 0.1 M CaCl₂, 0.15 M NaCl; pH 7.0) for 48 h, changing the washing solutions several times.

Example 6 – Production of hydrogels with lysozyme

The hydrogels are synthesized by covalent crosslinking of α,ω -activated PEG with lysozyme from chicken egg white. 7.5 – 15% (m/V) activated PEG are added to a 2.5 - 5% strength (m/V) protein solution in 0.1 M borate buffer (pH 9.0) and stirred until the onset of the gel point. Gels with a milky cloudiness are obtained.

The hydrogels are then stored at RT for 12 h to achieve complete crosslinking. Uncrosslinked PEG and protein are removed by incubating the hydrogel in 15 ml of physiological borate buffer (0.1 M H₃BO₃, 0.1 M MgCl₂, 0.1 M CaCl₂, 0.15 M NaCl; pH 7.0) for 48 h, changing the washing solutions several times.

Gel formation could be observed for the following PEG: PEG₃₅₀₀₀, PEG₂₀₀₀₀, PEG₁₅₀₀₀, PEG₁₀₀₀₀ and PEG₈₀₀₀.

Example 7 – Production of hydrogels with trypsin

The hydrogels were synthesized by covalent crosslinking of α,ω -activated PEG with bovine trypsin. 7.5 - 15% (m/V) activated PEG were added to a 2.5 – 5% strength (m/V) protein solution in 0.1 M borate buffer (pH 9.0) and stirred until the onset of the gel point. Gels with a milky cloudiness were obtained. The hydrogels were then stored at RT for 12 h to achieve complete crosslinking. Uncrosslinked PEG and protein were removed by incubating the hydrogel in 15 ml of physiological borate buffer (0.1 M H₃BO₃, 0.1 M MgCl₂, 0.1 M CaCl₂, 0.15 M NaCl; pH 7.0) for 48 h, changing the

washing solutions several times. Gel formation could be observed for the following PEG: PEG₁₀₀₀₀ and PEG₆₀₀₀.

Example 8 – Production of hydrogels with phosphatase

The hydrogels were synthesized by covalent crosslinking of α,ω -activated PEG with wheatgerm phosphatase. 10 – 15% (m/V) activated PEG were added to a 2.5% strength (m/V) protein solution in 0.1 M borate buffer (pH 9.0) and stirred until onset of the gel point. Brownish gels were obtained. The hydrogels were then stored at RT for 12 h to achieve complete crosslinking. Uncrosslinked PEG and protein were removed by incubating the hydrogel in 15 ml of physiological borate buffer (0.1 M H₃BO₃, 0.1 M MgCl₂, 0.1 M CaCl₂, 0.15 M NaCl; pH 7.0) for 48 h, changing the washing solutions several times. Gel formation could be observed for the following PEG: PEG₁₀₀₀₀ and PEG₆₀₀₀.

Patent Claims

1. Hydrogel comprising at least one protein and/or enzyme and/or SOD/catalase enzyme mimic and PEGs, and parts of proteins and enzymes and/or recombinant proteins and enzymes, the proteins and/or enzymes being connected to the PEGs via urea groups.
2. Hydrogel according to Claim 1, characterized in that the PEG has a molecular weight of from 8.000 to 18.000 g/mol, in particular from 10,000 to 15,000 g/mol.
3. Hydrogel according to Claims 1 and 2, characterized in that aliphatic or aromatic or araliphatic diisocyanates, in particular 1,6-hexamethylene diisocyanate, are employed to activate the PEGs.
4. Hydrogel according to Claims 1 to 3, characterized in that antibodies, matrix metalloproteases, enzyme inhibitors, peptides are used as proteins.
5. Hydrogel according to Claims 1 to 4, characterized in that free radical scavengers such as superoxide dismutase, catalase, glutathione peroxidase, myeloperoxidase and SOD/catalase enzyme mimics and/or combinations thereof are used as proteins.
6. Hydrogel according to Claims 1 to 5, characterized in that enzymes with antimicrobial activity, such as lysozyme and hydrolases, are employed as proteins.
7. Hydrogel according to Claims 1 to 6, characterized in that enzymes with phosphorylating activity, such as phosphatases and kinases, are employed as proteins.
8. Hydrogel according to Claims 1 to 7, characterized in that growth factors such as PDGF are employed as proteins.
9. Hydrogel according to Claims 1 to 8, characterized in that enzymes with proteolytic activity, such as collagenase, trypsin, elastase and/or combinations thereof, are employed as proteins.

10. Hydrogel according to Claims 1 to 9, characterized in that proteinogenic protease inhibitors such as aprotinin, soya bean trypsin inhibitor and alpha-2-macroglobulin and/or combinations thereof are employed as proteins.
11. Hydrogel according to Claims 1 to 10, characterized in that proteins are employed in mixtures.
12. Process for producing a hydrogel according to at least one of the preceding claims, characterized in that
 - e) anhydrous PEGs are reacted with diisocyanate in a solvent, where appropriate with the addition of a catalyst,
 - f) the solvent is removed from the resulting product of activated PEGs by filtration, washing or drying,
 - g) the activated PEGs are reacted in aqueous solution with proteins, the proteins being present in a buffer which is preferably chosen so that the proteins retain their biological activity,
 - h) where appropriate, purification steps and washes are carried out.
13. Process for producing a hydrogel according to Claim 12, characterized in that the hydrogel is dehydrated.
14. Use of the hydrogel according to at least one of the preceding claims as wound dressing, in particular for deep and extensive chronic wounds, and burns.
15. Use of the hydrogel according to at least one of the preceding claims for application to substrate materials which are permeable to air and water vapour, where appropriate, such as bandages, compresses, plasters, sheets, films and the like.

Abstract

Hydrogel comprising at least one protein and/or enzyme and/or SOD/catalase enzyme mimic and PEGs, and parts of proteins and enzymes and/or recombinant proteins and enzymes, the proteins and/or enzymes being connected to the PEGs via urea groups.




Figure 1

COMBINATION DECLARATION & POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **„Protein-containing hydrogels“** the specification of which is attached hereto.

-OR-

was filed on _____ as

Application Serial No. _____ and was amended _____

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)			Priority Claimed
<u>199 03 655.1</u> (Number)	<u>Germany</u> (Country)	<u>29/01/1999</u> (Day/Month/Yr. Filed)	<input checked="" type="checkbox"/> yes <input type="checkbox"/> no
_____ (Number)	_____ (Country)	_____ (Day/Month/Yr. Filed)	<input checked="" type="checkbox"/> yes <input type="checkbox"/> no

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

_____ (Application Serial No.)	_____ (Filing Date)	_____ (Status) (patented, pending, abandoned)
-----------------------------------	------------------------	---

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punished by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named Inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:
 Kurt G. Briscoe, Reg. No. 33,141; William C. Gerstenzang, Reg. No. 27,552; Carmella A. O'Gorman, Reg. No. 33,749; and Stephen G. Ryan, Reg. No. 39,015 all of 660 White Plains Road, Tarrytown, New York 10591-5144; William R. Robinson, Reg. No. 27,224; Mark A. Montana, Reg. No. 44,948 all of 721 Route 202-206, Bridgewater, New Jersey 08807; Lorimer P. Brooks, Reg. No. 15,155; Davy E. Zonerach, Reg. No. 37,267 all of 805 Third Avenue, 9th Floor, New York, NY 10022, my attorneys with full power of substitution and revocation.

Send Correspondence To: Norris McLaughlin & Marcus, P.A. 660 White Plains Road Tarrytown, N. Y. 10591-5144	Direct Telephone Calls To: (914) 332-1700
--	---

Full Name Of Sole or First Inventor Dr. Norbert Etnner	Inventor's Signature <i>Norbert Etnner</i>	Date 7.12.99
Residence Ludwig-Thoma-Str. 21, D-86551 Aichach, Germany	Citizenship German	
Post Office Address Ludwig-Thoma-Str. 21, D-86551 Aichach, Germany		
Full Name Of Second Inventor Dr. Michael Schink	Inventor's Signature <i>Michael Schink</i>	Date 29.11.99
Residence Falckweg 3, D-22605 Hamburg, Germany	Citizenship German	
Post Office Address Falckweg 3, D-22605 Hamburg, Germany		
Full Name Of Third Inventor Dr. Jörg Schreiber	Inventor's Signature <i>Jörg Schreiber</i>	Date 25.11.99
Residence Erlenkamp 20, D-22087 Hamburg, Germany	Citizenship German	
Post Office Address Erlenkamp 20, D-22087 Hamburg, Germany		
Full Name Of Fourth Inventor Dr. Wolfgang Meier	Inventor's Signature <i>Wolfgang Meier</i>	Date 29.11.99
Residence Jakobsbergerholzweg 4, CH-4053 Basel, Switzerland	Citizenship Swiss GERMAN	
Post Office Address Jakobsbergerholzweg 4, CH-4053 Basel, Switzerland		
Full Name Of Fifth Inventor Marc Sauer	Inventor's Signature <i>Marc Sauer</i>	Date 29.11.99
Residence Zöllnerstraße 39, D-29221 Celle, Germany	Citizenship German	
Post Office Address Zöllnerstraße 39, D-29221 Celle, Germany		
Full Name Of Sixth Inventor	Inventor's Signature	Date
Residence	Citizenship	
Post Office Address		
Full Name Of Seventh Inventor	Inventor's Signature	Date
Residence	Citizenship	
Post Office Address		